Net Income (Loss) Attributable to Parent in USD of Ambrx Biopharma Cayman, Inc. from 2019 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2019 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Jun 2023 was -$17,826,000.000, a 38.2% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$77,996,000.000, a 14.6% decline from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$68,079,000.000, a 312% decline from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$16,543,000.000, a 17.5% increase from 2019.
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$17,826,000 +$11,016,000 +38.2% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 -$15,302,000 +$7,345,000 +32.4% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023
Q2 2022 -$28,842,000 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 -$22,647,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023

Ambrx Biopharma Cayman, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$77,996,000 -$9,917,000 -14.6% 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023
2021 -$68,079,000 -$51,536,000 -3.1% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 -$16,543,000 +$3,519,000 +17.5% 01 Jan 2020 31 Dec 2020 20-F 26 Apr 2022
2019 -$20,062,000 01 Jan 2019 31 Dec 2019 20-F 26 Apr 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.